Cargando…
Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)
Oral squamous cell carcinoma (OSCC) frequently carries high epidermal growth factor receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an effective inhibitor of EGFR activity; however, resistance to this drug can occur, limiting therapeutic outcomes. Therefor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818869/ https://www.ncbi.nlm.nih.gov/pubmed/36611972 http://dx.doi.org/10.3390/cells12010179 |
_version_ | 1784865091659759616 |
---|---|
author | Chan, Chien-Yi Hong, Shih-Cing Chang, Chin-Ming Chen, Yuan-Hong Liao, Pin-Chen Huang, Chun-Yin |
author_facet | Chan, Chien-Yi Hong, Shih-Cing Chang, Chin-Ming Chen, Yuan-Hong Liao, Pin-Chen Huang, Chun-Yin |
author_sort | Chan, Chien-Yi |
collection | PubMed |
description | Oral squamous cell carcinoma (OSCC) frequently carries high epidermal growth factor receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an effective inhibitor of EGFR activity; however, resistance to this drug can occur, limiting therapeutic outcomes. Therefore, in the current study, we aimed to unveil key intracellular molecules and adjuvant reagents to overcome erlotinib resistance. First, two HSC-3-derived erlotinib-resistant cell lines, ERL-R5 and ERL-R10, were established; both exhibited relatively higher growth rates, glucose utilization, epithelial-mesenchymal transition (EMT), and invasiveness compared with parental cells. Cancer aggressiveness-related proteins, such as N-cadherin, Vimentin, Twist, MMP-2, MMP-9, and MMP-13, and the glycolytic enzymes PKM2 and GLUT1 were upregulated in ERL-R cells. Notably, ERL-R cells were sensitive to quercetin, a naturally-existing flavonol phytochemical with anti-cancer properties against various cancer cells. At a concentration of 5 μM, quercetin effectively arrested cell growth, reduced glucose utilization, and inhibited cellular invasiveness. An ERL-R5-derived xenograft mouse model confirmed the growth-inhibitory efficacy of quercetin. Additionally, knock-down of PKM2 by siRNA mimicked the effect of quercetin and re-sensitized ERL-R cells to erlotinib. Furthermore, adding quercetin blocked the development of erlotinib-mediated resistance by enhancing apoptosis. In conclusion, our data support the application of quercetin in anti-erlotinib-resistant OSCC and indicate that PKM2 is a determinant factor in erlotinib resistance and quercetin sensitivity. |
format | Online Article Text |
id | pubmed-9818869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98188692023-01-07 Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) Chan, Chien-Yi Hong, Shih-Cing Chang, Chin-Ming Chen, Yuan-Hong Liao, Pin-Chen Huang, Chun-Yin Cells Article Oral squamous cell carcinoma (OSCC) frequently carries high epidermal growth factor receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an effective inhibitor of EGFR activity; however, resistance to this drug can occur, limiting therapeutic outcomes. Therefore, in the current study, we aimed to unveil key intracellular molecules and adjuvant reagents to overcome erlotinib resistance. First, two HSC-3-derived erlotinib-resistant cell lines, ERL-R5 and ERL-R10, were established; both exhibited relatively higher growth rates, glucose utilization, epithelial-mesenchymal transition (EMT), and invasiveness compared with parental cells. Cancer aggressiveness-related proteins, such as N-cadherin, Vimentin, Twist, MMP-2, MMP-9, and MMP-13, and the glycolytic enzymes PKM2 and GLUT1 were upregulated in ERL-R cells. Notably, ERL-R cells were sensitive to quercetin, a naturally-existing flavonol phytochemical with anti-cancer properties against various cancer cells. At a concentration of 5 μM, quercetin effectively arrested cell growth, reduced glucose utilization, and inhibited cellular invasiveness. An ERL-R5-derived xenograft mouse model confirmed the growth-inhibitory efficacy of quercetin. Additionally, knock-down of PKM2 by siRNA mimicked the effect of quercetin and re-sensitized ERL-R cells to erlotinib. Furthermore, adding quercetin blocked the development of erlotinib-mediated resistance by enhancing apoptosis. In conclusion, our data support the application of quercetin in anti-erlotinib-resistant OSCC and indicate that PKM2 is a determinant factor in erlotinib resistance and quercetin sensitivity. MDPI 2023-01-01 /pmc/articles/PMC9818869/ /pubmed/36611972 http://dx.doi.org/10.3390/cells12010179 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chan, Chien-Yi Hong, Shih-Cing Chang, Chin-Ming Chen, Yuan-Hong Liao, Pin-Chen Huang, Chun-Yin Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
title | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
title_full | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
title_fullStr | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
title_full_unstemmed | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
title_short | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
title_sort | oral squamous cell carcinoma cells with acquired resistance to erlotinib are sensitive to anti-cancer effect of quercetin via pyruvate kinase m2 (pkm2) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818869/ https://www.ncbi.nlm.nih.gov/pubmed/36611972 http://dx.doi.org/10.3390/cells12010179 |
work_keys_str_mv | AT chanchienyi oralsquamouscellcarcinomacellswithacquiredresistancetoerlotinibaresensitivetoanticancereffectofquercetinviapyruvatekinasem2pkm2 AT hongshihcing oralsquamouscellcarcinomacellswithacquiredresistancetoerlotinibaresensitivetoanticancereffectofquercetinviapyruvatekinasem2pkm2 AT changchinming oralsquamouscellcarcinomacellswithacquiredresistancetoerlotinibaresensitivetoanticancereffectofquercetinviapyruvatekinasem2pkm2 AT chenyuanhong oralsquamouscellcarcinomacellswithacquiredresistancetoerlotinibaresensitivetoanticancereffectofquercetinviapyruvatekinasem2pkm2 AT liaopinchen oralsquamouscellcarcinomacellswithacquiredresistancetoerlotinibaresensitivetoanticancereffectofquercetinviapyruvatekinasem2pkm2 AT huangchunyin oralsquamouscellcarcinomacellswithacquiredresistancetoerlotinibaresensitivetoanticancereffectofquercetinviapyruvatekinasem2pkm2 |